Our Business Focus
Watson Pharmaceuticals, Inc. (NYSE: WPI), headquartered in Corona, California, is engaged in the development, manufacture, sale and distribution of proprietary (brand) and off-patent (generic) pharmaceutical products.
Watson pursues a strategy of generating revenue through three businesses - brand,
generic and distribution – with the majority of our revenue stemming from generic
product sales. This allows us to capitalize on the Company's proven ability to support
the development and commercialization of a broad range of brand and generic pharmaceutical
products.
A diversified, specialty pharmaceutical company, Watson markets its products through four core areas: specialty products, nephrology, urology, and generic products. These are areas where the Company has established strengths, reach and expertise.
The Company’s generic product line is one of the broadest in the industry, with approximately 150 product families. Watson is ranked third in the U.S. generic pharmaceutical marketplace in terms of number of prescriptions dispensed annually1.
The foundation of Watson’s business is an internal R&D program that leverages our expertise in drug delivery technologies and product development by taking promising product candidates through clinical studies.
With a robust generic and brand product pipeline, Watson currently has approximately 60 abbreviated new drug applications (ANDAs) pending approval with the Food and Drug Administration (FDA). In addition, Watson has a number of promising brand products in development that will complement the Company’s growing urology product portfolio.
Watson has expanded its access to numerous drug delivery technologies, including solid dosage form, oral controlled and sustained release, transdermal, and oral transmucosal. These capabilities, combined with seasoned leadership and strategic plans for long-term growth, are the tools for Watson's creation of consistent cash flow and an ongoing focus toward enhancing shareholder value.
1Source: IMS Health, December 2008
